2008 Press Releases
2007 Press Releases
2006 Press Releases
2005 Press Releases
Investor Events Calendar
December 20, 2006
Appointment of Dr Denis Wade to Board of Directors
December 11, 2006
ChemGenex Investigators Report Activity of Ceflatonin® and Gleevec® Combination Therapy in CML Patients Resistant to Gleevec® Alone
November 29, 2006
Chairman’s Address for ChemGenex Pharmaceuticals Limited Annual General Meeting
November 22, 2006
ChemGenex Appoints Dr Ian Nisbet as Vice-President of Oncology
November 14, 2006
ChemGenex Announces Granting of Fast Track Status for Ceflatonin® by FDA
September 20, 2006
Initial Patients Treated in Multinational Phase 2/3 Study of ChemGenex’s Ceflatonin®
August 02, 2006
ChemGenex Announces Publication Of Two New Clinical Studies Supporting Expanded Opportunity For Ceflatonin® Beyond CML To Other Leukemias
June 26, 2006
ChemGenex Teams with MolecularMD to Identify CML Patients with the T315I Drug Resistance Mutation for Phase 2/3 Clinical Trial of Ceflatonin®
June 19, 2006
ChemGenex Investigators Present Data at European Hematology Association Meeting Showing Success of Ceflatonin for Treating CML Patients Resistant to Gleevec®
June 13, 2006
ChemGenex Launches Multinational Phase 2/3 Study for CML Patients with the T315I Mutation
June 08, 2006
ChemGenex Discovery Highlighted At International Diabetes Conference
June 06, 2006
ChemGenex To Present At Pacific Growth Equities 2006 Life Sciences Growth Conference
May 11, 2006
ChemGenex To Present At Rodman & Renshaw 3rd Annual Global Healthcare Conference
May 08, 2006
ChemGenex Completes $A15 Million Capital Raising
April 03, 2006
Preclinical Progress Reported at American Association of Cancer Research Conference
March 23, 2006
New Preclinical Research Supports Ceflatonin® in Treatment of Acute Myeloid Leukemia (AML)
March 20, 2006
Orphan Drug Designation Granted by the U.S. FDA for Ceflatonin®
March 06, 2006
Cowen & Co 26th Annual Health Care Conference to Webcast ChemGenex Presentation
January 18, 2006
ChemGenex Granted U.S. Patent on Ceflatonin®’s Use for Treatment of Gleevec®-Resistant Patients with CML and Ph-Positive ALL
January 16, 2006
New Diabetes Research Contract With Merck KGaA
© 2005 ChemGenex Pharmaceuticals |
Terms of Use
